首页> 外文期刊>Bone >Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
【24h】

Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes

机译:二甲双胍,罗格列酮和胰岛素对2型糖尿病患者骨代谢的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Fracture risk is increased in individuals with type 2 diabetes (T2D). The pathophysiological mechanisms accentuating fracture risk in T2D are convoluted, incorporating factors such as hyperglycaemia, insulinopenia, and antidiabetic drugs. The objectives of this study were to assess whether different insulin regimens, metformin and rosiglitazone influence bone metabolism. We explored if the concentration of metformin and rosiglitazone in blood or improved glycaemic control altered bone turnover.
机译:背景:2型糖尿病(T2D)的个体中骨折风险增加。 诱惑T2D中骨折风险的病理生理机制是卷积的,掺入高血糖,胰岛素缺血和抗糖尿病药物等因素。 本研究的目的是评估不同的胰岛素方案,二甲双胍和罗格列酮是否影响骨代谢。 我们探讨了二甲双胍和罗格列酮血液中的血液或改善血糖控制的浓度改变了骨质周转。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号